1. Home
  2. MHF vs SPRO Comparison

MHF vs SPRO Comparison

Compare MHF & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$6.97

Market Cap

148.1M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHF
SPRO
Founded
1988
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
148.1M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MHF
SPRO
Price
$6.97
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
57.2K
241.8K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
4.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.92
$0.51
52 Week High
$6.79
$3.22

Technical Indicators

Market Signals
Indicator
MHF
SPRO
Relative Strength Index (RSI) 56.86 58.95
Support Level $6.89 $2.26
Resistance Level $6.97 $2.66
Average True Range (ATR) 0.05 0.08
MACD 0.01 0.01
Stochastic Oscillator 78.95 64.03

Price Performance

Historical Comparison
MHF
SPRO

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: